Cambridge Cognition’s CANTAB Plays Key Role in New Schizophrenia Drug Trials

Cambridge Cognition Holdings ( (GB:COG) ) has provided an announcement.

Cambridge Cognition Holdings announced significant results involving its CANTAB assessments, used in two Phase 3 clinical trials conducted by Bristol Myers Squibb. These trials evaluated the newly approved schizophrenia drug, Cobenfy, which marks a breakthrough in schizophrenia treatment by targeting M1 and M4 muscarinic receptors instead of dopamine receptors. The CANTAB assessments provided objective cognitive measures, demonstrating improvement in patients with cognitive impairments. This development underscores CANTAB’s effectiveness in improving cognitive performance measurement in schizophrenia treatments, and supports the adoption of digital assessment technologies to enhance the accuracy and efficiency of clinical trials.

More about Cambridge Cognition Holdings

Cambridge Cognition is a leading technology company specializing in digital health products that advance brain health research and treatment. The company offers three core products: scientifically validated CANTAB® assessments for cognitive function, a flexible eCOA platform for scalable data capture, and quality assurance tools for data integrity. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

YTD Price Performance: 0.0%

Average Trading Volume: 64,483

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £15.7M

For an in-depth examination of COG stock, go to TipRanks’ Stock Analysis page.